Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clonal divergence with acquired BRAF V600E in NSCLC with compound EGFR G719X/S768I after prolonged EGFR-TKI therapy.

Lung cancer (Amsterdam, Netherlands) - 1 Aug 2026

Hviid Camilla, Melchior Linea C, Berger Siv M S, Löfgren Johan O, Santoni-Rugiu Eric, Urbanska Edyta M

Abstract excerpt

BACKGROUND: Uncommon EGFR-mutations represent a heterogeneous subgroup of EGFR-mutant NSCLC with variable TKI sensitivity and limited evidence to guide treatment. Compound uncommon variants such as G719X/S768I are particularly rare. Acquired BRAF V600E is an infrequent resistance mechanism to EGFR-TKIs, mainly described in classical EGFR-mutations. CASE PRESENTATION: A 73-year-old woman with cardiomyopathy and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aniline Compounds
Share to Clonal Evolution

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Erlotinib Hydrochloride

Share to Indoles

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Pyrimidines

Source

Identifiers

PMID: 42398475
DOI: 10.1016/j.lungcan.2026.109517

Genes

EGFR
BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clonal divergence with acquired BRAF V600E in NSCLC with compound EGFR G719X/S768I after prolonged EGFR-TKI therapy.PMID 42398475Read ↗

Dynamic therapeutic response to osimertinib and immunotherapy in an EGFR L747S and L858R co-mutant NSCLC.Semantic proximity Read ↗

Characteristics and Clinical Outcomes of De Novo and Acquired Uncommon Compound EGFR Mutations in Patients With Advanced Non-Small Cell Lung Cancer: A Brief Report.Semantic proximity Read ↗

Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence.Semantic proximity Read ↗

Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review.Semantic proximity Read ↗

EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase InhibitorsSemantic proximity Read ↗

Characterization of a rare EGFR resistance mutation in a lung cancer patient with a long response to osimertinib: case report.Semantic proximity Read ↗

First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR-mutated lung cancer: a single institution's clinical practice experience.Semantic proximity Read ↗

Near-Complete Response to Osimertinib for Advanced Non-Small-Cell Lung Cancer in a Pretreated Patient Bearing Rare Compound Exon 20 Mutation (S768I + V774M): A Case Report.Semantic proximity Read ↗

Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer.Semantic proximity Read ↗

Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancerSemantic proximity Read ↗

Uncommon single and compound EGFR mutations: clinical outcomes of a heterogeneous subgroup of NSCLC.Semantic proximity Read ↗

Sequential EGFR T790M, MET c.3010C>G-Associated Exon 14 Alteration, and RET-CCDC6 Fusion in EGFR-Mutant NSCLC: A Case Report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.